Building the next generation of women's health technology.

Maternal mortality in the United States is the highest among high-income nations — and rising. Postpartum hemorrhage is preventable in most cases. Preeclampsia, hypertensive disorders of pregnancy, and endometriosis still lack the diagnostic tools and disease-modifying therapies they deserve. The gap between what we know and what reaches the bedside is wide.

At the University of Arizona, Dr. Goyal's program targets that gap from both ends. The wet lab generates mechanistic understanding of how early-life exposures program adult disease; the translational work converts that understanding into tools clinicians can use today. Arizona is a fitting base — a Southwest-serving academic medical center with a large patient population reflecting the demographics of US maternal health risk and a research ecosystem (BIO5, SWEHSC, Center for Innovation in Brain Science) that supports interdisciplinary work.

The "why now" is harder to ignore: large-language models, cheap genomic sequencing, validated digital-twin frameworks, and reimbursement openness toward remote monitoring have all matured in parallel. Tools that were impractical five years ago can be built and deployed today — if the people building them combine the clinical insight, scientific rigor, and commercial discipline the problem actually requires.